



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/86, 15/11, 5/10, A61K 48/00	A1	(11) International Publication Number: WO 97/42337 (43) International Publication Date: 13 November 1997 (13.11.97)
(21) International Application Number: PCT/GB97/01209 (22) International Filing Date: 2 May 1997 (02.05.97) (30) Priority Data: 9609261.4 2 May 1996 (02.05.96) GB (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): GREAVES, David, Robert [GB/GB]; Sir William Dunn School of Pathology, South Parks Road, Oxford OX1 3RE (GB). (74) Agent: REES, Marion; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: GENE EXPRESSION IN MONOCYTES AND MACROPHAGES		
(57) Abstract <p>The invention provides a cloned polynucleotide having the function of a transcriptional regulatory sequence (trs) and comprising: (a) a polynucleotide fragment having at least 70 % identity to the polynucleotide of SEQ ID NO. 2; (b) a polynucleotide which is complementary to the polynucleotide of (a); or (c) a polynucleotide comprising at least 15 sequential bases of the polynucleotide of (a) or (b).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

GENE EXPRESSION IN MONOCYTES AND MACROPHAGES

- 5 The present invention relates to the regulatory nucleotide sequences associated with the CD68 gene.

Background to the Invention

10 **Locus Control Regions**

Mammalian gene expression is regulated through cis- linked DNA sequences. Promoter sequences lie immediately 5' of the gene's transcription initiation site and enhancer sequences can lie within or close to the gene which they regulate. In 1987 it was shown that DNA
15 sequences found within 70 kilobases (kb) 5' of the human, β - globin gene on human chromosome 11 were able to effect high-level, copy number dependent expression of the human β -globin gene in erythroid cells of transgenic mice (1) Grosveld, F., *et al.* Cell, 1987, 51, 975-985. These DNA sequences which play a key role in the in vivo regulation of globin
20 gene expression were termed Dominant Control Sequences (DCR) - later renamed Locus Control Regions (LCRs). Locus Control Regions have been described for other red cell genes such as the genes of the human α -globin locus (2) Greaves, D.R., *et al.* Cell, 1989, 56, 979-986 and LCRs have been described which direct high level gene expression in other cell
25 types. Examples include the human CD2 gene which has a T-cell specific LCR and the 3' end of the C α immunoglobulin heavy chain locus which directs high level expression in B-cells (3) Madisen, L. and Groudine, M. Genes and Development, 1994, 8, 2212-2226.

- 30 The CD68 gene is expressed in all macrophage cells. The specificity of

expression in vivo is high. The origin of this specificity has been investigated and surprisingly it has been found that small regions of the CD68 gene are responsible.

5 **Summary of Invention**

The present invention therefore provides a cloned or isolated polynucleotide having the function of a transcriptional regulatory sequence (trs) and comprising:

- 10 (a) a polynucleotide fragment having at least 70% identity to the polynucleotide of Seq ID No. 2;
- (b) a polynucleotide which is complementary to the polynucleotide of (a); or
- (c) a polynucleotide comprising at least 15 sequential
- 15 bases of the polynucleotide of (a) or (b).

 Preferably the polynucleotide fragment has at least 80% identity to the polynucleotide of Seq ID No. 2, more preferably at least 90% identity to the polynucleotide of Seq ID No. 2. Most preferably the isolated

20 polynucleotide according to the invention comprises the polynucleotide of Seq ID No.2.

 The present invention further provides an isolated polynucleotide comprising the transcriptional regulatory sequence of CD68.

 The present invention additionally provides an isolated

25 polynucleotide comprising the transcriptional regulatory sequence of CD68 and a polynucleotide operatively linked thereto encoding a heterologous polypeptide.

 The present invention also provides a vector comprising a polynucleotide as defined herein and a host cell comprising the vector.

30 The present invention further provides a process for

producing a polypeptide which process comprises transforming or transfecting a cell with a vector as defined herein such that the cell expresses the polypeptide encoded.

In a further aspect this invention results from the discovery of DNA sequences exhibiting the properties of a locus control region associated with the CD68 gene. In one aspect the invention provides a vector for the integration of a gene into the genetic material of a mammalian host cell such that the gene may be expressed in the host cell, the vector comprising a promoter and the said gene and a Locus Control Region capable of eliciting host cell-type restricted, integration site independent, copy number dependent expression of said gene, characterised in that the Locus Control Region is located within a region extending from 14kb upstream to 25 kb downstream of the CD68 gene.

Functional definition of an LCR

Locus Control Regions are fundamentally different from other gene regulatory sequences in that they are not subject to position effects after integration into host cell chromosomes. Work with the human β -globin gene LCR revealed the three criteria which distinguish this class of DNA sequence from other regulatory sequences such as promoters and enhancers (1,4,5). Grosveld, F., *et al* Cell, 1987, 51, 975-985., Blom van Assendelft, M., *et al*, Cell, 1989, 56, 969-977., Talbot, D., *et al*. Nature, 1989, 338, 352-355.

1) LCRs direct position-independent expression of co-linked genes after integration into host genomes either in transgenic animals or in cell lines. As a consequence all transgenic animals carrying an intact copy of the transgene will express the transgene at a significant level. This is in sharp contrast to results obtained with other DNA sequences.

2) LCRs exhibit strict tissue specificity in the pattern of transgene expression. A human β -globin gene placed downstream of a human β - globin LCR is expressed only in red cells of transgenic mice

(1, 4). The exact same human β -globin gene fragment placed downstream of a human CD2 LCR is expressed at high levels in all T-cells but not red cells of transgenic animals (2). Greaves, D.R., *et al.* Cell, 1989, 56, 979-986.

5 3) LCRs direct high-level, copy number-dependent gene expression. Human β -globin transgenes can be expressed as efficiently on a per copy basis as endogenous murine β -globin genes in the erythroid cells of transgenic mice. When each transgene expresses at the same high level this leads to a direct relationship between transgene expression
10 and transgene copy number.

LCR's are thus expected to have a region providing chromatin opening activity, which region provides at least the first and third activities described above. An LCR generally contains at least one transcriptional regulatory sequence such as a promoter or enhancer in addition to the sequence
15 which provides chromatin opening activity.

The genetic diseases β -thalassaemia and sickle cell anaemia are caused by mutations within the human β -globin gene locus. All the red blood cells of the body are derived from a limited number of
20 haematopoietic stem cells found in the bone marrow. The demonstration that the β -globin LCR was able to direct red cell-specific expression regardless of its site of integration into the genome lead us to propose the idea of somatic gene therapy for β -thalassaemia and sickle cell anaemia by introducing, β -globin LCR vectors into haematopoietic stem cells and
25 using such transfected cells in bone marrow transplantation.

This is described in one of the proposed applications set out in the original β -globin LCR patents filed in 1987 and 1989 (UK patents 8718779 & 8904009.1).

The Locus Control Region (LCR) of the invention may be
30 located within a region extending from 5.5 kb upstream to 12 kb

downstream of the CD68 gene; particularly from 2940 base pairs (bp) upstream of CD68 gene to 335 bp downstream (shown in Seq ID No. 3) and more particularly within a 3 kb BstX1-BstX1 locus immediately upstream of the CD68 gene. The LCR may be a single continuous
5 sequence or may consist of two or more such sequences linked together with or without intervening polynucleotides. The LCR may consist of, be derived from, or correspond to one or more DNase hypersensitive sites. If the LCR of the naturally occurring gene locus comprises two or more discrete sub-sequences separated by intervening non-functional
10 sequences (for example, two or more hypersensitive sites) the vector of the invention may comprise an LCR comprising two or more of the sub-sequences linked together with all or part of the intervening sub-sequences removed.

The term "vector" as used herein connotes in its broadest
15 sense any recombinant DNA material capable of transferring DNA from one cell to another.

In another aspect the invention provides a mammalian host cell transformed with a vector as defined. The mammalian host cell is selected from macrophages, monocytes and dendritic cells and their
20 precursors.

In other aspects the invention provides: a method of producing a polypeptide by culturing a mammalian host cell as defined; a method of modifying mammalian host or stem cells by transformation with a vector as defined; transformed mammalian host or stem cells for use in
25 the treatment of a diseased condition in a human or animal body; and use of a vector as defined, or mammalian host or stem cells as defined, for the manufacture of a medicament for the treatment of a disease condition of the human or animal body caused by a gene deficiency.

Figures

30 Figure 1- restriction maps of cosmids containing the human

CD68 gene.

Figure 2 - DNA sequence of the 5' flanking regions of the human CD68 gene. (shown also in Seq ID No. 1)

Figure 3 - Northern blot analysis of RNA expression in stably transfected RAW cells.

Figure 4 - RT PCR analysis of CD68 and macrosialin RNAs in stably transfected RAW cells.

Figure 5 - Northern blot analysis of RNA expression in stably transfected RAW and A20 cells

Figure 6 - RT PCR analysis of CD68 and HPRT RNAs in stably transfected RAW and A20 cells.

Detailed Description

According to the present invention CD68 genes include human CD68, mammalian non-human CD68, for example mouse, dog, cat, rabbit, pig, cow, horse or rat CD68, or non-mammalian CD68. Mouse CD68 is known as macrosialin. Preferably the CD68 is human.

The nucleotide sequences which regulate transcription of CD68 gene are contained within the COSMID CD68C1 which is obtainable from a commercially available human genomic DNA cosmid library (Stratagene).

A transcriptional regulatory sequence (trs) generally comprises at least one promoter region and optionally at least one enhancer region. A trs may be a single continuous nucleotide sequence or may consist of two or more such sequences linked together with or without intervening polynucleotides. Trs regions are generally 5' (upstream) from the coding region but may also be found 3' (downstream) of the ATG start codon, for example in regions of coding sequence or in an intron. Specifically regions of human CD68 trs have been identified in the first intron downstream of the ATG start codon.

- 7 -

It the trs of the naturally occurring gene locus comprises two or more discrete sub-sequences separated by intervening non-functional sequences (for example, two or more super hypersensitive sites) the vector of the invention may comprise a trs comprising two or more of the sub-sequences linked together with all or part of the intervening sub-sequences removed.

The vector of the invention may be used to integrate into the genome an expression cassette which comprises a CD68 trs and a polynucleotide operatively linked thereto encoding a heterologous polypeptide. The vector may also be used to integrate a chimearic gene.

In either case the open reading frame or coding sequence of the gene or cassette is expressed in the host cell.

The vector comprises at least a trs and an open reading frame. An open reading frame may comprise introns. An open reading frame may comprise only coding regions.

A chimearic gene comprises at least a trs and an open reading frame. Optionally a chimearic gene will further comprise polynucleotide regions which regulate replication, transcription or translation or any other process important to the expression of the polynucleotide in a host cell.

The position of sequences relative to the CD68 gene is generally measured relative to the ATG start codon for upstream regions and relative to the stop codon for downstream regions.

Isolated or cloned means separate "by the hand of man" from its natural state; *i.e.*, that, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a naturally occurring polynucleotide or a polypeptide naturally present in a living organism in its natural state is not "isolated," but the same polynucleotide or polypeptide separate from the coexisting materials of its natural state is

"isolated", as the term is employed herein. As part of or following isolation, such polynucleotides can be joined to other polynucleotides, such as DNAs, for mutagenesis, to form fusion proteins, and for propagation or expression in a host, for instance. The isolated polynucleotides, alone or
5 joined to other polynucleotides such as vectors, can be introduced into host cells, in culture or in whole organisms. Introduced into host cells in culture or in whole organisms, such DNAs still would be isolated, as the term is used herein, because they would not be in their naturally occurring form or environment. Similarly, the polynucleotides and polypeptides may
10 occur in a composition, such as media formulations, solutions for introduction of polynucleotides or polypeptides, for example, into cells, compositions or solutions for chemical or enzymatic reactions, for instance, which are not naturally occurring compositions, and, therein remain isolated polynucleotides or polypeptides within the meaning of that term as
15 it is employed herein.

Expression cassettes themselves are well known in the art of molecular biology. Such an expression cassette contains all essential DNA sequences required for expression of the heterologous enzyme in a
20 mammalian cell. For example, a preferred expression cassette will contain a molecular chimaera containing a coding sequence an appropriate polyadenylation signal for a mammalian gene (i.e., a polyadenylation signal that will function in a mammalian cell), and enhancers and promoter sequences in the correct orientation.

25

Normally, two DNA sequences are required for the complete and efficient transcriptional regulation of genes that encode messenger RNAs in mammalian cells: promoters and enhancers. Promoters are generally located immediately upstream (5') from the start site of transcription.
30 Promoter sequences are required for accurate and efficient initiation of

transcription. Different gene-specific promoters reveal a common pattern of organisation. A typical promoter includes an AT-rich region called a TATA box (which is located approximately 30 base pairs 5' to the transcription initiation start site) and one or more upstream promoter elements (UPEs). The UPEs are a principle target for the interaction with sequence-specific nuclear transcriptional factors. The activity of promoter sequences is modulated by other sequences called enhancers. The enhancer sequence may be a great distance from the promoter in either an upstream (5') or downstream (3') position. Hence, enhancers operate in an orientation- and position-independent manner. However, based on similar structural organisation and function that may be interchanged, the absolute distinction between promoters and enhancers is somewhat arbitrary. Enhancers increase the rate of transcription from the promoter sequence. It is predominantly the interaction between sequence-specific transcriptional factors with the UPE and enhancer sequences that enable mammalian cells to achieve tissue-specific gene expression. The presence of these transcriptional protein factors (tissue-specific, trans-activating factors) bound to the UPE and enhancers (cis-acting, regulatory sequences) enables other components of the transcriptional machinery, including RNA polymerase, to initiate transcription with tissue-specific selectivity and accuracy.

Identity, as known in the art, is the relationship between two or more polynucleotide sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. Identity can be readily calculated (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds.,

Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity

5 between two polynucleotide sequences, the term is well known to skilled artisans (*Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Methods commonly
10 employed to determine identity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48:1073 (1988). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity are codified in computer programs.

15 Preferred computer program methods to determine identity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., *J. Molec. Biol.* 215: 403 (1990)).

Polynucleotides which have 70% or more identity with the
20 polynucleotides herein defined may differ from the defined sequences by virtue of at least one nucleotide substitution, addition, deletion, fusion or truncation in the polynucleotide.

One of the regions in the CD68 gene which has been found to be critical for the macrophage specificity of the CD68 gene is the region
25 which extends from the ATG start codon to the nucleotide approximately 80 base pairs upstream (5') to the ATG start codon. This will be referred to as the -80bp region.

A second region which has been found to be critical is the region downstream (3') of the ATG start codon of the CD68 gene and
30 which contains the first PU.1 site downstream of the start codon. A PU.1

- 11 -

site is a DNA sequence capable of binding the etf - family transcription factor PU.1 which is expressed in macrophages, neutrophils and B-cells.

The first PU.1 site downstream of the start codon is comprised within an intron. In human CD68 the intron containing the first
5 PU.1 site is from nucleotide 32 to nucleotide 137 downstream of the start codon.

The region containing the first downstream PU.1 site and the -80bp region when operatively linked provide macrophage specificity. Seq. ID No 2 comprises the sequence of human CD68 from -80bp to the ATG
10 start codon and comprises a PU.1 site and the first intron downstream of the ATG start codon.

A further region which has been found to be critical in providing specificity is the region containing the PU.1 site approximately 110bp upstream of the ATG start codon. Thus the nucleotide sequence
15 from the ATG start codon to approximately 150 base pairs upstream from the ATG start codon confers enhanced macrophage specific expression.

A further region which confers specificity is at the PU.1 site which is found approximately 432 base pairs upstream from the ATG start codon. Thus the nucleotide sequence which extends from the ATG start
20 codon to approximately 460 base pairs upstream from the start codon confers further enhanced macrophage specific expression.

High macrophage specificity is observed when a gene is expressed under the control of any of the above sequences. High macrophage specificity may also be obtained when a gene is expressed
25 under the control of the region which extends from 2940 base pairs upstream of the ATG start codon to 335 base pairs downstream of the TGA stop codon.

The first sequence of the first intron of macrosialin has also been determined and is also a polynucleotide of the invention. The whole
30 sequence of the open reading frame of macrosialin is given in Seq. ID No

4. Oligonucleotide primers derived from the murine macrosialin cDNA sequence were used to PCR amplify a 1759bp fragment from Sv129 mouse genomic DNA. The genomic PCR product was cloned into the InVitrogen plasmid vector pCRII and the macrosialin gene sequence was
5 determined by dye terminator DNA sequencing of double stranded DNA. DNA coding sequence is shown in uppercase and underlined, 5' and 3' untranslated regions and intervening sequences are shown in lowercase. The ATG initiator and TGA termination codons are underlined.

The present invention therefore provides a polynucleotide
10 comprising
(a) a polynucleotide fragment having at least 70% identity to a polynucleotide as defined herein;
(b) a polynucleotide which is complementary to the polynucleotide of (a); or
15 (c) a polynucleotide comprising at least 15 sequential bases of the polynucleotide of (a) or (b)

Preferably the polynucleotide fragment has at least 80% identity to a polynucleotide as herein defined, more preferably at least 90% identity to the polynucleotide as herein defined. Most preferably the
20 isolated polynucleotide according to the invention comprises the polynucleotide as herein defined.

Specifically the present invention provides a polynucleotide comprising an isolated polynucleotide comprising:
(a) a polynucleotide fragment having at least 70% identity
25 to the polynucleotide of Seq ID No. 3;
(b) a polynucleotide which is complementary to the polynucleotide of (a); or
(c) a polynucleotide comprising at least 15 sequential bases of the polynucleotide of (a) or (b).

30 A preferred nucleotide according to the invention comprises

the region containing the first PU1 site and the -80bp region.

A further preferred nucleotide comprises the region from +150 bp to -137 bp relative to the ATG start codon.

A still further preferred nucleotide comprises the region from
5 +460 bp to -137 bp relative to the ATG start codon.

The nucleotide sequence of each of these regions may be determined from Seq. ID No 3 which shows the sequence of cosmid CD68C1 from 2951bp 5' of the CD68 ATG initiation codon (shown in bold type) to 2090 bp 3' of the CD68 TGA termination codon (shown in bold
10 type). Intron sequences are in lowercase, and CD68 coding and 3' untranslated regions are underlined.

Each of the nucleotide sequences of the invention may be used in inverted form.

More than one copy, for example two, three or four copies, of
15 each of the regions described above may be used to control expression of a single gene. When more than one copy of a region is used, the copies are preferably operably linked. The regions may be used in combination or separately.

The sequence ID No. 2 may be used as a probe to locate the
20 sequence ID No. 3, which may then be manipulated according to conventional techniques using known restriction sites.

In a search for macrophage-specific gene regulatory sequences recombinant cosmids were isolated containing the human CD68 gene by PCR screening of a human genomic DNA library in the
25 cosmid vector pWE15. Human CD68 is the human homologue of mouse macrosialin, a protein which is found in the phagosomal compartment of all monocytes and macrophages. Two types of human CD68 cosmids were obtained which contain the complete CD68 gene with 14 kilobases of 5' flanking sequences and 25 kilobases of 3' flanking sequences (Figure 1).

30 The cosmids were used as probes to demonstrate that the

human CD68 gene is located on the short arm of human chromosome 17. The cosmids were used as templates to determine the DNA sequence of the CD68 gene and 1870bp of the CD68 promoter (Figure 2).

The CD68 cosmids were transfected into the murine
5 macrophage cell line RAW264.7 and stably transfected RAW cell
populations and polyclones were selected by growth in G418. Northern
blot analysis of total RNA isolated from G418 resistant RAW cells was
performed using a radiolabelled human CD68 gene probe (Figure 3A) and
a mouse lysozyme probe to control for RNA loading and transfer
10 (Figure 3B). Total RNA prepared from human peripheral blood
mononuclear cell (PBMC) cultures was analysed on the same filter. The
human CD68 cosmid transfected RAW cells express very high levels of
human CD68 mRNA of the expected size. The levels of human CD68
mRNA are higher in cosmid transfected RAW cells than in cultured human
15 monocytes. This result was confirmed by analysis of transfected RAW cell
RNA by Reverse Transcription - Polymerase Chain Reaction (RT-PCR)
analysis using human CD68 and murine macrosialin specific PCR primers
(Figure 4). The transfected human CD68 gene is expressed at higher
levels than the endogenous mouse macrosialin gene.

20 The same CD68 cosmid DNAs were transfected into murine
A20 B- cells and 3T3 fibroblasts. Northern blot analysis of CD68 RNA
expression showed levels of CD68 mRNA at least 50 times lower than that
observed in murine macrophage cell line RAW264.7 transfected with the
same cosmids (Figure 5). These results were confirmed by RT-PCR
25 analysis of transfected cell RNA using CD68 and HPRT specific PCR
primers (Figure 6).

Single cell clones from G418 resistant RAW cell populations
have been isolated and will be analysed to determine if there is a direct
relationship between transgene copy number and transgene expression in
30 transfected RAW264.7 cells which would be predicted if there is a

macrophage-specific Locus Control Region in the CD68 cosmids.

The extremely high level of human CD68 mRNA seen in cosmid transfected RAW cells (Figures 3,4 and 5) show that important macrophage-specific genetic regulatory elements are contained within the CD68 cosmids cosCD68C1 and cosCD68G1. Our previous work using the human lysozyme promoter in transgenic animal experiments has shown an important role for intervening sequences and poly A+ addition sequences for transgene expression in macrophages (7,8) Dighe, A.S., *et al.* Immunity, 1995, 3, 657-666. and Clarke, S., *et al.* Proc.Natl. Acad. Sci. (USA), 1996, 93; 1434-1438.. A role for intervening sequences in ensuring efficient transgene expression has been described in a number of other systems.

Development of a macrophage-specific gene expression vector

In order to express heterologous genes at a high level in monocytes and macrophages it would be desirable to design a CD68 expression vector. Such a vector should include all the DNA sequences in the human CD68 cosmids which direct high-level, macrophage-specific gene expression along with the CD68 introns and poly A+ sequences and unique restriction enzyme recognition sites for the insertion of cDNAs encoding heterologous genes of interest.

To facilitate manipulation of the human CD68 gene sequences present in cosmid cosCD68C1 a 20kb EcoRI fragment which contains the complete human CD68 gene along with 5.5kb of 5' flanking and 12.5kb of 3' flanking sequences was cloned into the unique EcoRI site of the plasmid vector Bluescript SK- (Stratagene) to give the recombinant plasmid pCD68R1A (Figure1). Two further recombinant plasmids were derived from pCD68R1A which contain the 5' flanking and 3' flanking sequences of the human CD68 gene, pCD68RS1 and pCD68SR1 (Figure 1). In order to engineer the insertion of cDNAs encoding heterologous

genes immediately downstream of the CD68 gene promoter and immediately upstream of the CD68 gene's ATG initiation codon the plasmid pCD68RS1 was digested with the restriction enzyme BstX1 and a 3kb BstX1 fragment was cloned into the plasmid vector Bluescript SK(Stratagene) after treatment with T4 DNA polymerase which removes the CD68 ATG initiation codon (Figure 2). The human CD68 genomic DNA fragments present in the recombinant plasmids shown in Figure 1 allow for the development of a versatile and easily manipulated human CD68 expression system for use in macrophage cell lines, transgenic animals and human primary cells.

Table 1 Promoter activity of CD68 promoter 5' deletion series in transiently transfected RAW264.7 and P388.D1 cells.

RAW264.7 or P388.D1 cells were electroporated in the presence of 20µg of the indicated CAT reporter plasmids and 5µg of the β-galactosidase reporter plasmid pcDNA3 β-gal. Forty eight hours post transfection cell lysates were assayed for β-galactosidase and CAT enzyme activity as described in Experimental Procedures. Cell lysate CAT enzyme activities were corrected for transfection efficiency and the data is expressed as a percentage of the CAT enzyme activity obtained with the SV40 promoter/enhancer plasmid pCATControl in the same experiment. All cell lysate CAT enzyme activities were within the linear range of the assay as determined from a CAT enzyme dilution series analysed in the same experiment. The data shown are from a single transfection experiment and the relative promoter activities were reproducible in at least three independent transfection experiments with each construct in both cell lines.

Table 2 Comparison of myeloid gene promoter activities in transiently transfected murine macrophage cell lines.

P388.D1 or RAW264.7 cells were electroporated in the presence of 20µg of the indicated CAT reporter plasmids and 5µg of the β-galactosidase reporter plasmid pcDNA3 β-gal. Twenty four hours post transfection cell lysates were assayed for β-galactosidase and CAT enzyme activity as described in Experimental Procedures. Cell lysate CAT enzyme activities were corrected for transfection efficiency and expressed as a percentage of the CAT enzyme activity obtained with the SV40 promoter/enhancer plasmid pCATControl in the same experiment.

All cell lysate CAT enzyme activities were within the linear range of the assay as determined from a CAT enzyme dilution series analysed in the same experiment. The data shown are from a single transfection experiment and the promoter activities were reproducible in at least two independent transfection experiments with each construct.

15

Table 3

Plasmid	Gene	Promoter	Accession No
-2940CD68pCAT	hCD68	-2940 to +2*	This paper
hLZMpCAT	hLysozyme	-517 to +26	X57103
mLZMpCAT	mLysozyme	-487 to +11	D13263
CD11b pCAT	hCD11b	-1706 to +91	M76724
c-fes pCAT	h c-fes	-446 to +71	X06292
hMSRpCAT	h MSR	-487 to +11	D13263

20 Table 3 shows Myeloid promoters used in this study

All myeloid gene promoter fragments were cloned into the multiple cloning site of the CAT reporter vector pCATBasic (See Experimental Procedures). Human genes are denoted by the prefix h and murine genes by the prefix m.

25

Promoter coordinates shown are taken from the given Genbank accession

numbers and the major transcription initiation site is denoted as +1 except for CD68 where the A of the ATG translation initiation codon is denoted as +1 (*).

5

Table 5 The effect of the CD68 first intron in transiently transfected RAW264.7 and CHO cell lines.

- 10 RAW264.7 cells were electroporated in the presence of 20µg of the indicated CAT reporter plasmids and 5µg of the β-galactosidase reporter plasmid pcDNA3 β-gal. Forty eight hours post transfection transfected cell lysates were assayed for β-galactosidase and CAT enzyme activity. CHO cells were transfected with 4.5µg of the indicated
- 15 CAT reporter plasmids and 0.5µg of the β-galactosidase reporter plasmid pcDNA3 β-gal complexed with 50µg of the cationic lipid Lipofectamine (Gibco BRL). Cell lysate CAT enzyme activities were corrected for transfection efficiency and expressed as a percentage of the CAT enzyme activity obtained with the SV40 promoter/enhancer
- 20 plasmid pCATControl analysed in the same experiment. All cell lysate CAT enzyme activities were within the linear range of the assay as determined from a CAT enzyme dilution series analysed in the same experiment. The data shown are from a single transfection experiment and the promoter activities were reproducible in at least three
- 25 independent transfection experiments with each construct in each cell line.

Table 4 The effect of the CD68 first intron on CD68 and HIV promoters

- 30 RAW264.7 and P388.D1 cells were electroporated in the presence of

- 19 -

20µg of the indicated CAT reporter plasmids and 5µg of the β-galactosidase reporter plasmid pcDNA3 β-gal. Forty eight hours post transfection transfected cell lysates were assayed for β-galactosidase and CAT enzyme activity. Cell lysate CAT enzyme activities were corrected
5 for transfection efficiency and expressed as a percentage of the CAT enzyme activity obtained with the SV40 promoter/enhancer plasmid pCATControl analysed in the same experiment. All cell lysate CAT enzyme activities were within the linear range of the assay as determined from a CAT enzyme dilution series analysed in the same
10 experiment. The data shown are from a single transfection experiment and the promoter activities were reproducible in at least three independent transfection experiments with each construct in each cell line.

15

METHODS

Construction of promoter reporter plasmids

A 2940bp BstXI fragment was purified from an EcoRI - SpeI fragment
20 subcloned from cosCD68C1. The BstXI fragment was rendered blunt ended by incubation with T4 DNA polymerase and all four dNTPs and cloned into the EcoRV site of pBluescript SK- (Stratagene) to give plasmid pCD68Bst3-2. The 3' BstXI site contains the CD68 ATG initiation codon which was removed by the 3' exonuclease activity of T4 DNA polymerase.

25 A Hind III - XbaI fragment containing 2940 bp of DNA upstream of the CD68 ATG codon was cloned into the reporter vector pCAT Basic (Promega, Genbank accession number X65322) to give the plasmid -2940 CD68pCAT. Plasmid -2940-CD68pCAT was digested with XhoI, BglII or SstI and overhanging ends filled in by treatment with the Klenow fragment
30 of DNA polymerase or T4 DNA polymerase before ligation of phosphorylated HindIII linkers. Following digestion with HindIII and XbaI,

5' truncated CD68 promoter fragments were gel purified and subcloned into HindIII and XbaI digested pCATBasic to give the plasmids - 2258CD68pCAT, -1576CD68pCAT and -951CD68pCAT. All other CD68 promoter deletions were prepared by PCR using plasmid -2940 CD68pCAT as a template and 5' oligonucleotide primers which added a HindIII site and a common 3' PCR primer which spanned the XbaI cloning site of plasmid -2940 CD68pCAT (listed in Table 1). Amplified fragments were digested with HindIII and XbaI, gel purified and subcloned into HindIII and XbaI digested pCATBasic to give the plasmids -333CD68pCAT, -232CD68pCAT, -150CD68pCAT and -80CD68pCAT. The first intron of the CD68 gene was PCR amplified using primers 5' ccggaattcTGCTGGGGCTACTGGCAG and 5' tgatctagaGTCCCCTGGGCTTTTGGCAG which added EcoRI and XbaI sites (underlined). Following EcoRI and XbaI digestion the CD68 intron fragment was cloned into pCD68Bst3-2 digested with EcoRI and XbaI to give plasmid pCD68BstIVS and a 3022bp HindIII - XbaI fragment was cloned into pCATBasic to give the plasmid -2940 IVSpCAT. The HIV minimal LTR construct HIV pCAT is from Lew et al. (1991) Mol. Cell. Biol. 11, 182-191. Construct HIV IVS pCAT was made by ligating the EcoRI to XbaI IVS I fragment of pCD68BstIVS into the unique BglII site in the HIV tar sequence. All CD68 promoter reporter constructs were sequenced using M13 reverse and CAT primers and shown to exactly match the CD68 promoter sequence shown in Figure. A 1.7 kb HindIII-BamHI (blunt) fragment containing CD11b sequences from -1706 to +91 was excised from the plasmid pB202 (Dzjemmis *et al*, 1995, Blood, 85, 319-329 and cloned between the HindIII and XbaI (blunt) sites of pCATBasic to give the clone CD11b pCAT. A 516bp Hind III - Xba I fragment containing c-fes sequences from -446 to +71 was excised from the plasmid p446 (a kind gift of Celeste Simon, H ydemann et al., 1996) and cloned between the Hind III and Xba I sites of pCATBasic to give the plasmid c-fes pCAT. Other

myeloid gene promoters were cloned by PCR using the primers designed from published sequences listed in Table I with cloned DNA or human genomic DNA templates. A Sma-BamHI fragment containing the SV40 early splice and polyadenylation sequences from plasmid pMSG
5 (Pharmacia) was ligated into SmaI-BamHI digested plasmid pH2KBS which contains the 1.6kb H2K cDNA cloned into the EcoRV site of pBluescript (a kind gift of Dr D. Mokophidis) to give the plasmid pH2KSV. A 2.5kb HindIII-BamHI fragment of pH2KSV was rendered blunt ended by treatment with T4 DNA polymerase and ligated into SmaI digested CD68
10 promoter plasmid pCD68Bst3-2 to give plasmid pCD68-H2KSV and the same pH2KSV fragment was ligated into HincII digested human lysozyme promoter plasmid pBH7.4 (Clarke et al. 1996) to give hLZM-H2KSV. Plasmid pkb-HindIII contains a 7.4kb HindIII genomic DNA fragment of the H2Kb gene (Weiss et al., 1992).

15 Supercoiled plasmid DNAs were prepared from 500ml cultures of E.coli by NaOH/SDS lysis and purified by equilibrium centrifugation in CsCl/ethidium bromide gradients followed by phenol/chloroform extraction and ethanol precipitation (Sambrook, Fritsch & Maniatis 1989).

20

Mammalian cell culture and transient transfection

The murine macrophage cell lines RAW264.7 and P388.D1 were maintained in RPMI 1640 medium (Gibco BRL) supplemented with 10%
25 heat inactivated foetal calf serum (FCS) (Sigma), 100 units ml⁻¹ penicillin, 100 µg ml⁻¹ streptomycin, 2mM glutamine and 10mM Hepes (pH 7.0). CHO K1 cells were maintained in Ham's F-12 medium (Gibco BRL) supplemented with 10% FCS, antibiotics and glutamine. All cells were grown at 37°C in a humidified incubator in 5% CO₂/air. RAW264.7 and
30 P388.D1 cells were grown to confluence in T175 flasks, harvested in

Phosphate Buffered Saline (PBS) and washed once and resuspended in Optimem 1 serum free medium (Gibco BRL) for RAW cells or RPMI 1640 (no FCS) for P388D1 cells. Cells were counted and adjusted to a final density of 4×10^7 cells ml⁻¹. Aliquots of 2×10^7 cells (0.5ml) were mixed
5 with 50 µg CAT reporter plasmid DNA and 5 µg pcDNA3 b-galactosidase plasmid DNA, added to a 0.4cm electrode gap electroporation cuvette (BioRad) and shocked in a BioRad GenePulser (300V, 960 µFD) at room temperature. Cells were recovered immediately into 10ml of cell growth medium which had been pre-warmed to 37°C and plated into 35mm and
10 9cm diameter tissue culture petri dishes (Nunc). Cells were analysed 24 or 48 hours post electroporation for transfection efficiency by staining fixed permeabilised cells with 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal, Sigma) as described (Hogan et al. 1994). Transient transfection efficiencies of between 20 and 30% were routinely obtained with P388.D1
15 murine macrophages and after optimisation transient transfection efficiencies in excess of 40% could be obtained with RAW264.7 cells. CHO cells were grown to 70-80% confluence in 9cm petri dishes, washed twice with Optimem before addition of 5ml of plasmid DNA:cationic lipid complex (5 µg DNA:50 µg Lipofectamine (Gibco BRL) in Optimem). After 6-16
20 hours incubation the medium was aspirated, cells were washed twice with PBS and recovered into complete medium for 24-36 hours before analysis. X-gal staining and FACS analysis routinely showed CHO cell transient transfection efficiencies in excess of 40%.

25 Reporter gene assays

Transfected cells were harvested by scraping in PBS, washed once with PBS and cell pellets were resuspended in 100µl 0.25M Tris-HCl (pH 7.8) and subjected to three rounds of freeze thaw lysis. Cell
lysates were assayed for β-galactosidase enzyme activity using the
30 colorimetric substrate chlorophenolred β-D-galactopyranoside (CPRG,

Boehringer Mannheim) in a 96 well plate assay in 50mM potassium phosphate buffer (pH7.3) with 2mM MgCl₂. Enzyme activity was determined by spectrophotometry at 570nm after 30 minutes incubation at 37°C using dilutions of purified E.coli β -galactosidase enzyme (Sigma) to generate a standard curve. CAT enzyme activity of cell lysates was determined after heat treatment (65°C, 20 minutes) using 10 μ Ci ¹⁴C labeled chloramphenicol (54Ci mmol⁻¹, Amersham) as substrate in a 125 μ l reaction in 0.25M Tris-HCl (pH 8.0) containing 0.2 mg ml⁻¹ n-butyryl CoA as cofactor. CAT enzyme activity was measured by determining the amount of butyryl-¹⁴C chloramphenicol extracted into mixed xylenes (Aldrich) after a 2 hour incubation at 37°C (Seed ref). A CAT enzyme standard curve was generated using dilutions of purified CAT enzyme (Promega) in each experiment and all CAT enzyme assays using transfected cell extracts were within the linear range of the enzyme assay.

15

Figure 1. Restriction maps of cosmids containing the human CD68 gene.

Recombinant cosmids containing the human CD68 gene in the vector pWE15 were isolated by PCR screening of pools of robotically picked Ampicillin resistant HB101 colonies using PCR primers CD68 L1 & CD68 L2. CD68 PCR positive single colonies were used to prepare cosmid DNA which was analysed by restriction mapping and Southern blotting using radioactively labelled CD68 gene probes. Sites for the restriction enzymes Spe I (Spe), Cla I and Not I are shown. Not I sites in brackets (Not I) are derived from the pWE15 cosmid vector cloning site and flank the human genomic DNA insert.

25

Below the map of cosmid cosCD68C1 is shown the position of a 20kb EcoRI fragment cloned into the plasmid vector pBluescriptSK- to give the recombinant plasmid pCD68R1A. The positions of other cosCD68C1 restriction fragments cloned into the plasmid vector pBluescriptSK- are also indicated. The 3kb BstXI fragment the 3' end of

30

which contains the CD68 gene ATG initiation codon is indicated.

Figure 2. DNA sequence of the 5' flanking region of the human CD68 gene.

5 The DNA sequence of the 5' flanking region of the CD68 gene was determined by double strand sequencing using the CD68 cosmids as template and oligonucleotide primers derived from the published human CD68 cDNA sequence (17). The initiator Methionine encoding ATG codon of the CD68 gene which is contained within a BstXI
10 restriction enzyme recognition site is boxed. CD68 coding regions are underlined and intervening sequences inferred from comparison with the published CD68 cDNA sequence are delimited by vertical arrows. The sequence has not yet been confirmed on both strands, ambiguities in multiple sequence reads are indicated by lowercase letters according to
15 the IUPAC-IUB standards described in Nuc. Acids. Res. 13, 3021-3030 (1985). Dots in the sequence indicate a chemical bond.

Figure 3. Northern blot analysis of RNA expression in stably transfected RAW cells.

20 Total RNA was prepared from G418 resistant RAW cell populations (derived from at least 10,000 independent G418 resistant colonies) or polyclones (derived from 50 -100 independent G418 resistant colonies). RAW cells were transfected with 10 µg of supercoiled or Pvu I linearised CD68 cosmids or a pcDNA3 CAT plasmid which confers
25 resistance to G418.

 Total RNA (10 µg) was denatured with formaldehyde, subjected to agarose gel electrophoresis, transferred to nylon membranes and hybridised with radioactively labelled human CD68 and mouse lysozyme probes. For comparison total RNA (5 µg) prepared from human
30 THP1 cells treated with PMA for 24 hours and human PBMC cultures was

analysed. A 6 hour autoradiographic exposure is shown.

Figure 4. RT PCR analysis of CD68 and macrosialin RNAs in stably transfected RAW cells.

5 RNAs (10 µg) prepared from the G418 resistant RAW cell populations analysed by Northern blotting in Figure 3 were used to prepare oligo dT-primed cDNA in a reverse transcription (RT) reaction in a final volume of 100 µl. Control RT reactions omitting reverse transcriptase were performed using the same RNA samples (-RT). A 30 cycle Polymerase
10 Chain Reaction (PCR) using macrosialin and CD68- specific primers was performed using 1 µl of the neat RT reaction or indicated dilutions as template. The RT PCR products were analysed by agarose gel electrophoresis and the position of mouse macrosialin and human CD68 PCR products of the predicted sizes are indicated.

15

Figure 5. Northern blot analysis of RNA expression in stably transfected RAW and A20 cells.

 RAW and A20 B-cells were transfected with 10 µg of supercoiled or Pvu I linearised CD68 cosmid or a pcDNA3 CAT plasmid
20 which confers resistance to G418. Total RNA (10 µg) prepared from G418 resistant cell populations was denatured with formaldehyde, subjected to agarose gel electrophoresis, transferred to nylon membranes and hybridised with a radioactively labelled human CD68 probe. For comparison total RNA prepared from human THP1 cells treated with PMA
25 for 24 hours (5 µg) and human PBMC cultures (2 µg) was analysed. A 6 hour autoradiographic exposure is shown.

Figure 6. RT PCR analysis of CD68 and HPRT RNAs in stably transfected RAW and A20 cells.

30

 RNAs (10 µg) prepared from the G418 resistant RAW cell

- 26 -

populations analysed by Northern blotting in Figures 3 & 5 were used to prepare oligo dT-primed cDNA in a reverse transcription (RT) reaction in a final volume of 100 μ l. A 30 cycle Polymerase Chain Reaction (PCR) CD68- and HPRT- specific primers was performed using 1R1 of the neat
 5 RT reaction or indicated dilutions as template. The RT PCR products were analysed by agarose gel electrophoresis and the position of human CD68 PCR and HPRT PCR products of the predicted sizes are indicated.

Table 1

10

This table shows the effect of deleting CD68 5' promoter sequences in RAW and P388.D1 transfections

-2940pCAT	38.6	78.4
-666pCAT	37.5	74.4
-575pCAT	48.4	129.5
-460pCAT	71.6	132.2
-333pCCAT	30.5	112.3
-232pCAT	34.4	96.4
-150pCAT	11.6	176
-80pCAT	0.64	9.5
pCATBasic	0	2
pCATControl	100	100
Plasmid construct	RAW264.7	P388.D1

Table 2

15

This table compares the level of CAT reporter gene activity of plasmids with different myeloid gene promoters in P388.D1 and RAW264.7

pCAT Control	100	100
--------------	-----	-----

- 27 -

pCAT Basic	0	8.4
-2940 CD681VS	117	163.9
-2940 CD68 pCAT	39	50
hLZM pCAT	17.6	66
mLZM pCAT	20.1	73.3
CD11b pCAT	42	23
-c-fes pCAT	4.8	47.3
hMSR pCAT	3	35.5
CAT Reporter Plasmid	RAW264.7	P388.D1

Table 4

This table compares the level of CAT reporter gene activity of plasmids with CD68 and HIV minimal LTR promoters in P388.D1 and RAW264.7 cells

pCAT Control	100	100
pCAT Basic	0	8.4
-2940 CD681VS	117	163.9
-2940 CD68pCAT	39	50
HIV IVS pCAT	0.8	15
HIVpCAT	0.8	69
CAT Reporter Plasmid	RAW264.7	P388D1

Table 5

This table shows the effect of adding the CD68 IVS intron on to different

CD68 promoter fragments in RAW and CHO cells

pCAT Control	100	100
pCAT Basic	0	0
-2940 CD68pCAT	31	56
-2940 IVS	154	63
-80 pCAT	0.6	5
-80 IVS	53	1.9

Plasmid construct	RAW264.7	CHO
-------------------	----------	-----

5 **Potential Applications for the CD68 LCR**

The Macrophage as a delivery vehicle for gene therapy

Macrophages have several important advantages over other cell types for delivering therapeutic gene products in a range of important human diseases

Macrophages have a high biosynthetic capacity.

Macrophages secrete physiologically significant amounts of cytokines, growth factors, inflammatory mediators, proteases, protease inhibitors and other important biologically active macromolecules.

Macrophages have a limited life span.

After commitment tissue resident and recruited macrophages undergo only one or two cell divisions at most, this would be a distinct advantage in many human gene therapy protocols.

Macrophages are found in virtually all tissues.

The presence of macrophages in virtually every tissue in the body in significant numbers increases the utility of an LCR which directs macrophage-specific gene expression. The presence of macrophages in

- 29 -

the lung and gut allows for recombinant DNA delivery to macrophages by a number of different routes.

Macrophages are rapidly recruited into sites of inflammation.

The ability to direct heterologous gene expression in a cell type which is
5 recruited to sites of inflammation offers unique avenue for therapeutic
intervention in chronic inflammatory disease.

Somatic Gene Therapy

There are currently no human monogenic disorders described which specifically affect macrophage function which would be candidates for "classical" somatic gene therapy. However the CD68 LCR could be used to drive the expression of therapeutic gene products in human macrophages in a whole range of important human diseases. Candidate genes would include: Local delivery of soluble IL-1Ra to inflamed rat knee joints by recombinant retroviral vectors has been shown to be 10 000 times more efficient than systemic administration of sIL-1RA in reducing experimentally-induced arthritis (9) Makarov, S.S., *et al* Proc. Natl. Acad. Sci. (USA), 1996, 93; 402-406.

Currently there is much interest in anti TNF- α therapy in treatment of toxic shock syndrome and a number of autoimmune diseases such as rheumatoid arthritis which afflicts 1% of the UK population. Many important human diseases are the result of a failure in regulation of the immune system. Macrophages and cytokines secreted by macrophages such as IL-12 and IL-10 play a key role in regulating T-lymphocyte function. Macrophages-specific expression of trans-dominant negative IL-4 receptors could find application in autoimmune diseases such as Ulcerative Colitis and Crohn's Disease.

Apo E and several other gene products have been proposed to play a key role in the development of atherosclerotic plaques which are the cause of blood vessel occlusion in atherosclerosis and strokes. Apo E expressed in macrophages present in atherosclerotic plaques might find application in the treatment of vascular occlusion (10). CD68 is present in the macrophage derived foam cells found in human disease tissue and we have shown the mouse homologue of CD68, macrosialin, to be present at high levels in the atherosclerotic plaques of an apo E^{-/-} mouse model of atherosclerosis.

The murine homologue of CD68, macrosialin has been

reported to bind oxidised LDL (11). Overexpression of **human CD68**, **murine macrosialin** or **human Macrophage Scavenger Receptor** in macrophages present in atherosclerotic plaques may usefully reduce the amount of atherogenic oxidised LDL in atherosclerotic lesions.

5 Chronic Granulomatous Disease (CGD) is a genetic disease caused by mutation of the **NAPDH oxidase** gene. CGD patients fail to make reactive oxygen metabolites in their phagocytic cells which kill bacteria and hence patients suffer from recurrent bacterial infections. Expression of NAPDH oxidase in macrophages of CGD patients by
10 somatic gene therapy would be highly beneficial (12).

 There are several relatively rare human genetic diseases which can be treated by providing purified proteins which can be taken up by defective cells to correct their genetic defect. Examples include **Beta cerebrosidase** in patients with Gaucher's disease and other genes
15 defective in lysosomal storage disorders (13). A particular attraction of the CD68 LCR for treatment of lysosomal storage diseases is the fact that CD68 is expressed in microglia, mononuclear phagocytic cells resident in the brain. Some microglial cells in adults are derived from recruited blood monocytes and hence the CD68 LCR may offer the possibility of
20 expressing therapeutic gene products in the brain via recruited blood monocytes transfected with CD68 LCR vectors.

Treatment of infectious diseases

 Several important human pathogens survive and replicate in
25 the endosomal compartment of macrophages. These include the causative agents of tuberculosis, leishmaniasis and leprosy. The HIV virus survives and replicates in monocytes. Targeting γ -interferon production to macrophages infected with *Mycobacterium bovis* could be a viable strategy for treatment of Tb. The delivery of HIV **decoy tar s qu nces** and other
30 anti HIV reagents to monocytes and macrophages would create a pool of

monocytes resistant to HIV infection. Similar gene therapy protocols for the "intracellular vaccination" of T-lymphocytes have been proposed.

Macrophage Expression Systems

5 The original β - globin LCR vectors have been used to develop expression systems for the over production of heterologous gene products in cultured erythroid cell lines(14). The CD68 LCR could be used for over expression of heterologous genes in human and murine macrophage cell lines for instance in the production of cytokines and
10 soluble receptors whose pattern of glycosylation was important for their biological activity.

Genetic Vaccination

 Recently it was shown that naked DNA could be used in
15 animals to confer protective immunity against lethal virus challenge and to elicit significant humoral antibody responses. Current protocols for genetic vaccination use standard mammalian expression vectors based on the SV40 or HCMV promoters and enhancers. Heterologous genes are expressed in myofibres but the cells presenting foreign antigen for the
20 elaboration of an effective immune response are unknown (15). Using a CD68 LCR vector to target heterologous gene expression to macrophages and possibly dendritic cells should increase the efficiency and efficacy of genetic vaccination protocols.

Immunotherapy

25 Dendritic cells process antigens for presentation to cells of the immune system. Human dendritic cells expressing the CD68 antigen are important in conferring tolerance in organ transplant rejection and autoimmune diseases. A CD68 LCR will allow for the genetic targeting of
30 an important subset of Dendritic cells grown in culture from bone marrow or

peripheral blood precursors.

Compositions

The invention also relates to compositions comprising the polynucleotide, vector or transfected cell. Thus, the polypeptides of the present invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to a subject. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a polypeptide of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration.

Kits

The invention further relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, reflecting approval by the agency of the manufacture, use or sale of the product for human administration.

Administration

Polynucleotides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.

The pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific indication or indications. In general, the compositions are administered in an amount of at least about 10 µg/kg body weight. In most cases they will be administered
5 in an amount not in excess of about 8 mg/kg body weight per day. Preferably, in most cases, dose is from about 10 µg/kg to about 1 mg/kg body weight, daily. It will be appreciated that optimum dosage will be determined by standard methods for each treatment modality and indication, taking into account the indication, its severity, route of administration,
10 complicating conditions and the like.

In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

Alternatively the composition may be formulated for topical
15 application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may
20 also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.

For administration to mammals, and particularly humans, it is
25 expected that the daily dosage level of the active agent will be from 0.01 mg/kg to 10 mg/kg, typically around 1 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of the average case. There

can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

A vaccine composition is conveniently in injectable form. or may be administered by other techniques, for example a gene gun using, for example, gold particles, or *ex vivo* Conventional adjuvants may be employed to enhance the immune response.

A suitable unit dose for vaccination is 0.5-5 μ g/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks.

With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals.

The polynucleotide sequences, vectors and host cells of the present invention may be used in the treatment of infectious diseases including viral and bacterial infections such as HIV and TB, inflammatory diseases, cardiovascular diseases, rheumatoid arthritis, atherosclerosis, restinosis, cancer, for example cancer of the bowel, colon, breast or lung.

Other LCR Patents

The published LCR most similar in targeting transgene expression to macrophages is the Class II LCR . This element has been claimed to direct expression to (presumably activated) macrophages, dendritic cells and B-lymphocytes (16). Our data with stably transfected murine macrophage line RAW 264.7 and the murine B-cell line A20 already show the CD68 cosmid direct expression which is restricted to macrophages (Figures 5 8 6).

References

1. Grosveld, F., Blomvan Assendelft, M., Greaves, D.R. and Kollias, G.
Position-independent, high-level expression of the human β - globin

gene in transgenic mice. Cell, 1987, 51, 975- 985.

2. Greaves, D.R., Wilson, F.D., Lang, G. and Kioussis, D. Human CD2
3' flanking sequences confer high- level, T- cell specific, position
5 independent gene expression in transgenic mice.
Cell, 1989, 56, 979- 986.
3. Madisen, L. and Groudine, M.
Identification of a locus control region in the immunoglobulin heavy-
10 chain locus that deregulates c-myc expression in plasmacytoma and
Burkitt's lymphoma cells.
Genes and Development, 1994, 8, 2212- 2226.
4. Blom van Assendelft, M., Hanscombe, O., Grosveld, F. and Greaves,
15 D.R.
The β - globin dominant control region activates homologous and
heterologous promoters in a tissue- specific manner.
Cell, 1989, 56, 969- 977.
5. Talbot, D., Collis, P., Antoniou, M., Vidal, M., Grosveld, F. &
20 Greaves, D.R.
A dominant control region from the human, β globin locus conferring
integration site- independent gene expression.
Nature, 1989, 338, 352- 355.
- 25 6. Therexsys and gene therapy
Nature Medicine, 1995, 1, 502
7. Dighe, A.S., Campbell, D., Hsieh, C-S, Clarke, S., Greaves, D.R.,
Gordon, S., Murphy, K.M. and Schreiber, R.D.
30 Tissue-specific targeting of cytokine unresponsiveness in transgenic

mice.

Immunity, 1995, 3, 657- 666.

8. Clarke, S., Greaves, D.R., Ping Chung, L., Tree, P. and Gordon, S.
5 The human lysozyme promoter directs reporter gene expression to
activated myelomonocytic cells in transgenic mice.
Proc. Natl. Acad. Sci. (USA), 1996, 93; 1434- 1438.
9. Makarov, S.S., *et al.*
10 Suppression of experimental arthritis by gene transfer of interleukin 1
receptor antagonist cDNA
Proc. Natl. Acad. Sci. (USA), 1996, 93; 402- 406.
10. Linton, M.F., Atkinson, J.B. and Fazio, S.
15 Prevention of Atherosclerosis in Apolipoprotein E-deficient mice by
bone marrow transplantation.
Science (1995) 267; 1034-1037.
11. Ramprasad, M.P., Fischer, W., Witzum, J.L., Sambrano, G.R.,
20 Quehenberger, O. and Steinberg, D.
The 94-97-kDa mouse macrophage membrane protein that
recognises oxidized low density lipoprotein and phosphatidylserine-
rich liposomes is identical to macrosialin, the mouse homologue of
human CD68.
25 Proc. Natl. Acad. Sci. (USA), 1995), 92; 9580-9584.
12. Segal, A.W.
The NAPDH oxidase and chronic granulomatous disease.
Molecular Medicine Today, 1996, 2; 129- 135.

13. Zhou, X.Y., Morreau, H., Rottier, R, Davis, D., Bonten, E., Gillemans, N., Wenger, D., Grosveld, F.G., Doherty, P., Suzuki, K., Grosveld, G.C. and d'Azzo, A.
Mouse model for the lysosomal disorder galactosialidosis and
5 correction of the phenotype with overexpressing erythroid precursor cells.
Genes and Development (1995) 9; 2623- 2634.
14. Needham, M. *et al.*
10 LCR/MEL: A versatile system for high-level expression of heterologous proteins in erythroid cells.
Nucleic Acids Research, 1992, 20; 997- 1003.
15. Maurice, J.
15 Gene vaccines
Molecular Medicine Today, 1995, 1; 64-71.
16. Carson, S. and Wiles, M.
20 Far upstream regions of class 11 MHC Ea are necessary for position-independent, copy-dependent expression of an Ea transgene.
Nucleic Acids Research, 1993, 21; 2065- 2072.
17. Holness, C. and Simmons, D.
25 Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins.
Blood, 1993, 81; 1607-1613.

Seq ID No. 1

REVERSE-COMPLEMENT of: Drg 237.Con check: 1236 from: 1 to: 3601

Drg237.rev Length: 3601 April 29, 1996 11.13 Type N Check: 6126

```

1  TGTCTGGAA CCCAGGTGCC TACCTGGTCT GCTGCATATT TGTTTTCTCT
51  TCCAGCATGG AGATATGGnA CCAAAAGGAA CGAGTGCTCA GAGTTTTGAT
101 TACCAnTGAC CTGCTGGTGA GTAGAGGGAA CTGATAGCAA AGGCAGAAGG
151 GAGGATCCAA GGTGATTCCC TCTCCAAGGC AAGTTCGGAA AGTAGCAGCT
201 TGGAATAGAA TCTGGCATGC CTAAGGCCTT TGGGGAAGTG GGATGCTTAT
251 TTCCTCTGCC TTCCTTGGCT GCCCACATGG ATGCCTAAGT GTCTTCCCTC
301 CGGGATAGAG TGTCTCCGT GCACATGCTG AAGAGTTGTC TTTCTTGACG
351 TAGGCCAGAG GCATTGATGT GCAGCAGGTT TCTTTAGTCA TCAAcTATGA
401 CcTTCCCAAC AACAGGGAAA ACTATATCCA CAGGTAAGCG TAGATCTGGA
451 ACATTCCCAAn ACCCTTTCAC ACcTGGCCcT CCCTGGGCTT AAAGCTCCTG
501 ATATTCCCTCA TCCCCTTCCT TGTTTTCCAG AATCGGTCGA GGTGGACGGT
551 TTGGCCGTAA AGGTGTGGCT ATTAACATGG TGACAGAAGA AGACAAGAGG
601 AyTcTTCGAG ACATTGAGAC cTTCTACAAC ACCTCCATTG AGGAAATGCC
651 CCTCAATGTT GCTGACCTCA TCTGAGGGGC TGTCcTGCCA CCCAsCCCCA
701 gCCAsgGcTC AAkYtTGGG GGCTGAGGAk CwgCAGGAGG GGGGAGGGAA
751 GGGAGCCAAG GGATGGACAT CTTGTcAtTT TTTTtCTTT GAATAAATGT
801 CACTTTTTGA GGCAAAAGAA GGAACCGTGA ACATTTTAGA CACCCTTTTC
851 TTTGGGGTAG GCTCTTGCCC CAGGCGCCGG CTCTTCTCCC AAAAAAAAAA
901 AAAAAACAcT AaTCCATTTC CCTAACcTag TAACcTCCAG ATCCCAGAGG
951 CTCTCCTCAC CTCAGCTGAG CTCCTTTGAA AGTGATTCAA GGGAcTATGT
1001 CAcTCAGCcT CATTTGcTGG ACCAAATcTG GAGGGAGAAC CCCTAAAACC
1051 CcTAAGTGAG GTTGCCAGG GGGTTGTCCC CAGGTGGGGG GAAGCAGGGG
1101 AGAGAAAATG GTAGCCATTT TtACATTGTT TTGTATAGTA TTTATTGATT
1151 CAGGAAACAA ACACAAAATT cTGAATAAAA TGAATTGGAA ACTGCCTGTT
1201 TGGGCTTCTC ATTTCTtACC TCCCCTTCCC TCTCCACCT GmTAcTGGGT

```

SUBSTITUTE SHEET (RULE 26)

1251 GCATcTCTGC T.CCCCCCTT .CCCCAGCAG ATGGTTACCT TTGGGCTGTT
1301 GCTTTCTTGT CACCATCTGA GTTCTCAGAC GCTGGAAAGC CATGTTCTCG
1351 GCTCTGTGAA tGACAATGcT GAcTGGAGTG CTGCCCCCTCT GTAAAGGGcT
1401 GGGTGTGGAT GGTCAACAAGC CcTtCACATG CyTCAGCCAA GAgGAAGTAG
1451 tACAGGGgTC AGCCCAgAgg TCCAGGGGAA AgGAgtgGAA AcCGATTTC
1501 CCACCAA.GG GAgGGGcTG TAcCTCAGcT GTTCCCATAg cTACTTGCCA
1551 CAACTGCCAA GCAAgTTTCG cTGAgTTtGA CACATGG.AT CCC.TGTGGA
1601 TCAAcTGCCc TAGGAcTCcG TTTGCACCCA TgtgACacTG ttGAcTTTGC
1651 CCTGAcgAa. gCAgggcCAa cagtccccta AcTTAATtAC aAaAAcTAAT
1701 GAcTAAGAgA gAgGTGGcTA gAgCTGAgGC CCCTG.AgTC AgGcTGTGGG
1751 TGGGATCaTc tCCAgTACAG GAAgtGAGAc TTTCATTT.C ctCctTTcCA
1801 Ag.AgAgGGc TGAgGGAgCa gGGTTgAgCa ActGGTGCAg ACAGCCTAgc
1851 TGGActTTGG GTgAgGc..g gtTCAgCCAT gAgGctGGcT gTgCttTtcT
1901 cGGGGGcCCT GcTGGGGcTA cTGGCAGGTA AGGAGGAAG AgGcTGAGGG
1951 GAGGGGG..c CCCTGGGAGG GAGCcTG.CC CTGGGTTGct AACCATcTCC
2001 T....ct.CT GCCAAAAGCC CAGGGGACAG GGAATGAC.T GTCCTCACAA
2051 AAAATCAGcT ACTTtGcTGC CATCctTCAC GGTGACACCC ACGGtTACAG
2101 AGAGCACTGG AACAAcCAGC CACAGGACTA CCAAgAGCCA CAAAACCACC

SUBSTITUTE SHEET (RULE 26)

41

Seq ID No 2

5 TTCCAAGAGAGGGCTGAGGGAGCAGGGTTGAGCAACTGG
TGCAGACAGCCTAGCTGGACTTTGGGTGAGGCGGTTCAGCCAGGAATCC
TGCTGGGGCTACTGGCAGgtaaggagCCCAG

10 gaaggaggctgaggggagggggccctgggagggagcctgccctggg
ttgctaaccatctcctctctgccaaaagCCCAG

SUBSTITUTE SHEET (RULE 26)

Seq ID No. 3

aattcgggttctccaatcccctgggtcactttgctcttgtgcacgctttcc
agtctttcagcgtaagccagagtcattcccaaggatgctggtttctctct
gggggaagagctgctctgtgatggagcccatgctgtcatctgagcctct
ggcttccctgccagtgcagccctggcagtgtcctacttcccagggtggt
gtctgcctggcggaaggtcctgggcaaaggatcagtctttgtactctga
gagcagactacttggctcctctctgttttttatcagcgaagttggatata
tctctcccacatttccctaatacatatgctatatattggcttttttttct
tctctagCCCCCAAATACATCAAGATGTTTGTACTGGATGAAGCTGACGA
AATGTTAAGCCGTGGATTCAAGGACCAGATCTATGACATATTCCAAAAGC
TCAACAGCAACACCCAGgtgagggcagtcttgcttgaatagctaagatt
cttgaaaaatagtaagtgccaggggaaaccaaataactggattcttgagcc
tttttatgcatctgcttcagtttttaggtgtggctaggggaaggagcaggc
ctcaggaaggaaccagcactctaagactggcctttttttccactagGTAG
TTTTGCTGTCAGCCACAATGCCTTCTGATGTGCTTGAGGTGACCAAGAAG
TTCATGAGGGACCCATTCCGGATTCTTGTCAAGAAGGAAGAGTTGACCCT
GGAGGGTATCCGCCAGTTCTACATCAACGTGGAACGAGAGgtggggccca
gtgcaggaggcgggcctggtagtgagttgttgggtatagcccctgactga
tttttgtcccccaacctccagGAGTGGAAGCTGGACACACTATGTGACTT
GTATGAAACCCTGACCATCACCCAGGCAGTCATCTTCATCAACACCCGGA
GGAAGGTGGACTGGCTCACCGAGAAGATGCATGCTCGAGATTTCACTGTA
TCCGCCATGgtgtgtttgcccgtgccagcctgttgtgggtctgcccgtc

agaagtgtcctacttgaagccagggttcctggaacccaggtgcctacctg
gtctgctgcatatttgttttctcttcagCATGGAGATATGGACCAAAAG
GAACGAGACGTGATTATGAGGGAGTTTCGTTCTGGCTCTAGCAGAGTTTT
GATTACCACTGACCTGCTGgtgagttagagggaactgatagcaaaggcaga
agggaggatccaaggtgattccctctccaaggggacatcagtgcctctca
ggaaagtagcagcttggaatagaatctggcatgcctaaggcctttgggga
actgggatgcttatttccctctgccttccttgggtgcccacatggatgcct
aagtgtcttccctccgggatagagtgtcctccgtgcacatgctgaagagt
tgtctttcttgacgtagGCCAGAGGCATTGATGTGCAGCAGGTTTCTTTA
GTCATCAACTATGACCTTCCCACCAACAGGGAAAACCTATATCCACAGgta
agcgtagatctggaacaytcccntaccnttcacacctggccctccctgg
gcttaaagctcctgatattcctcctcccttccttggttttccagAATCGG
TCGAGGTGGACGGTTTGGCCGTAAAGGTGTGGCTATTAACATGGTGACAG
AAGAAGACAAGAGGANTCTTCGAGACATTGAGACCTTCTACAACACCTCC
ATTGAGGAAATGCCCCCTCAATGTTGCTGACCTCATCTGAGGGGCTGTCCT
GCCACCCASCCCCAGCCAGGGCTCAAAGTCTGGGGGCTGAGGACCTGCAG
GAGGGGGGAGGGAAGGGAGCCAAGGGATGGACATCTTGTCATTTTTTTTT
CTTTGAATAAATGTCACTTTTTGAGGCAAAAGAAGGAACCGTGAACATT
TAGACACCCTTTTTCTTTGGGGTAGGCTCTTGCCCCAGGCGCCGGCTCTTC
TCCCAAAAAAAAAAAAAAAAAACACTAATCCATTTCCCTAACCTAGTAACCT
CCAGATCCCAGAGGCTCTCCTCACCTCAGCTGAGCTCCTTTGAAAGTGAT
TCAAGGGACTATGTCACTCAGCCTCATTGCTGGACCAAATCTGGAGGGA
GAACCCCTAAAACCCCTAAGTGAGGTTGCCAGGGGGTTGTCCCCAGGTG

SUBSTITUTE SHEET (RULE 26)

GGGGGAAGCAGGGGAGAGAAAATGGTAGCCATTTTACATTGTTTTGTAT
AGTATTTATTGATTCAGGAAACAAACACAAAATTCTGAATAAAATGACTT
GGAAACTGCCTGTTTGGGCTTCTCATTTCTTACCTCCCCTTCCCTCTCCC
ACCTGCTACTGGGTGCATCTCTGCTCCCCCTTCCCCAGCAGATGGTT
ACCTTTGGGCTGTTGCTTTCTTGTCACCATCTGAGTTCTCAGACGCTGGA
AAGCCATGTTCTCGGCTCTGTGAATGACAATGCTGACTGGAGTGCTGCC
CCTCTGTAAAGGGCTGGGTGTGGATGGTCACAAGCCCCTCACATGCCTCA
GCCAAGAGGAAGTAGTACAGGGGTGAGCCCAGAGGTCCAGGGGAAAGGAG
TGGAACCGATTTCCCCACCAAGGGAGGGGCCTGTACCTCAGCTGTTCC
CATAGCTACTTGCCACAAGTCCAAGCAAGTTTCGCTGAGTTTGACACAT
GGATCCCTGTGGATCAACTGCCCTAGGACTCCGTTTGCACCCATGTGA
CACTGTTGACTTTGCCCTGACGAA.GCAGGGCCAACAGTCCCCTAACTTA
ATTACAAAATAATGACTAAGAGAGAGGTGGCTAGAGCTGAGGCCCTG
AGTCAGGCTGTGGGTGGGATCATCTCCAGTACAGGAAGTGAGACTTTCA
TTTCCTCCTTTCCAAGAGAGGGCTGAGGGAGCAGGGTTGAGCAACTGG
TGCAGACAGCCTAGCTGGACTTTGGGTGAGGCGGTTCAGCCATGAGGC
TGGCTGTGCTTTTCTCGGGGGCCCTGCTGGGGCTACTGGCAGgtaaggag
gaaggaggctgaggggagggggccctgggagggagcctgccctggg
ttgctaaccatctcctctctgccccaaagCCCAGGGGACAGGGAAT
GACTGTCCTCACAAAAATCAGCTACTTTGCTGCCATCCTTCACGGTGA
CACCCACGGTTACAGAGAGCACTGGAACAACCAGCCACAGGACTACCAAG
AGCCACAAAACCACCACTCACAGGACAACCACCACAGGCACCACCAGC

SUBSTITUTE SHEET (RULE 26)

CACGGACCCACGACTGCCACTCACAACCCACCACCAGCCATGGA
AACGTCACAGTTCATCCAACAAGCAATAGCACTGCCACCAGCCAGGGACC
CTCAACTGCCACTCACAGTCCTGCCACCACTAGTCATGGAAATGCCACGG
TTCATCCAACAAGCAACAGCACTGCCACCAGCCCAGGATTCACCAGTTCT
GCCCACCCAGAACCACCTCCACCCTCTCCGAGTCCTAGCCCAACCTCCA
AGGAGACCATTGGAGACTACACGTGGACCAATGGTTCCCAGCCCTGTGT
CCACCTCCAAGCCCAGATTCAGATTCGAGTCATGTACACAACCCAGGGTG
GAGGAGAGgtaaagctaaaactgggggatgagaggggagggaggcaggac
tggttataggctcagaggggaagaaggaagaggggacaggnaaccttggcc
ggcatcgcatgcagtccttgtagaccttcagtcctttaacttcgcagGGCT
GGGGTATCTCTGTNCTGANCCCCAACAGAACCAAGGTCCAGGGAAGCTGT
GGGGGTGCCCATCCCCACCTGCTTCTCTCATTCCCCTATGGACACCTCAG
CTTTGGATTTCATGCAGgtatagccatgacctcagtcctcaccctcactca
gcctcccggcgccctccctcccaatcccacacgctactccttcctctg
tggagagggataccacctgcgccttcctcttcgccccacagGACCTCC
AGCAGAAGGTTGTCTACCTGAGCTACATGGCGGTGGAGTACAATGTGTC
CTTCCCCCACGCAGCACgtaagtaacctccttcctttctcattgctacc
actagacgccagggttcctgaaaggactaagctggggccagggaggtgg
ataggatctgaccttcctcactcctccagAGTGGACATTCTCGGCTCAG
AATGCATCCCTTCGAGATCTCCAAGCACCCCTGGGGCAGAGCTTCAGTTG
CAGCAACTCGAGCATCATTCCTTTCACCAGCTGTCCACCTCGACCTGCTCT
CGCTGAGGCTCCAGGCTGCTCAGCTGCGCAGACAGGGGTCTTTGGGCAA
Agtaagacctactccttccttcctagaatcctcccactgcactgaa

aaccccttccccagggccataagccactcatctctcttcttaacccccca
aatctcgctctcccagcttgatggtacagggcagctttctttccatc
ctctacaagactctgccagtttcccccttttatcactgctgagtcactgc
ggtgagctcctcaccaatctcctactccccagcatccccccattccctcc
tcccacctttatcccaaccagcacgtcactgcaaatacctacctgccta
tccttcggccagGTTTCTCCTGCCCCAGTGACCGGTCCATCTTGCTGCCT
CTCATCATCGGCCTGATCCTTCTTGCCCTCCTCGCCCTGGTGCTTATTGC
TTTCTGCATCATCCGGAGACGCCATCCGCCTACCAGGCCCTCTGAGCAT
TTGCTTCAAACCCAGGGCACTGAGGGGGTTGGGGTGTGGTGGGGGGT
ACCCTTATTTCTCGACACGCAACTGGCTCAAAGACAATGTTATTTTCCT
TCCCTTTCTTGAAGAACAAAAAGAAAGCCGGGCATGACGGCTCATGCCTG
TAATCCCAGCACTTTGGGAGGCTGAGGCAGGTGGATCACTGGAGGTCAGG
AGTTTGAGACCAGCCTGGCCAACATGGTGAAACCCTGTCTCTACTAAAAA
TACAATTAGCCAGGTGTGGCGGCGTAATCCCAGCTGGCCTGTAATCCCAG
CTACTTGGGAGGCTGAGGCAGAACTGCTTGAACCCAGGAGGTGGAGGTTG
CAGTGAGCCGTCATCGCGCCACTGAGCCAAGAGTCGCGCCACTGCACTCC
AGCCTGGGCGACAGAGCCAGACTGTCTCAAATAAATAAATATGAGATAAT
GCAGTCGGGAGAAGGGAGGGAGAGAATTTTATTAAATGTGACGAACTGCC
CCCCCCCCCCCCCCCCAGCAGGAGAGCAGCAAAATTTATGCAAATCTTG
ACGGGGTTTTCTTGTCTGCCAGGATTAAAAGCCATGAGTTTCTTGTC
CATGCCTTTCTATGCCTTCCATGGCTGGGTCTCAGGGAGCCGGAAGCAGC
TGCTGAGGAGGGATGAAAATGTCAGTGTGTGACGATGCCTCATGGGTTCA

SUBSTITUTE SHEET (RULE 26)

CCCCCAAAGCCTGGCACAGCTGGTGTGGGTCTGCCGTGCCTCCCTTCC
TTCCTCCTCTTGGGGCCACTGGCTGCTCCAGTTCCCCATCCGTGGCAAGC
CGGTAGAGCCATTCATCCCCGCAGCCTTCTTCCTGACCCTCGTACAGTTT
CAAATGCAGCAGACAGCCAAAGCAATGAGTGGGGGGCTGTGGAACCTTCAT
TCCCAAAGGCAGCGCCAGTGGCTCCTGAGCAATGAGAATGTCCTGTCCTG
TCCACCATATTCAAGGCCAGCAGAAGAGCCCGATTAAACCCTCGCAGCGA
CCTGGCATGCTCCTATCCCACCTGCAAGGGGTGAATCAAGAAGGAGCAG
TGGGTACTCTGACCTCCACTGGGGGCTCCTGGGAACAGCATGCCCCCAC
ACGGGGCCACCTGCCAAGCCTAACTTCATGCCCCAGTACTTGAGATGAG
GAGTGTCACTCTCAGGACAGCCAAGGTCCAGATTCTAGAAAGGACCTCCC
AGATGGCCACAGCCTGCACCAGCAGTGAGCGCCAGTCCCACCCATTACAG
CTGGCTACGGCGCAATCCCTGGGAGCCAGGATGAGCAGCACCCCCCAGCC
GTAGGAGCCCCAGGAGGCTTCCGGCTTCCAAGGCCMAGAGACTGCCCCAC
AAGGSAGCCCTCACCTGGCAGGGCCCAGCAAGCCCCACCTCTGCCTGCAG
ACATCCGTGTGACCTTGTAGACTTTGGAGGGGGGCCCCAAAGGGCTGATC
CACAGCGGAATGACGCACGGGTGGGCACCGTGGGTGGCGTCCCGGCGGT
CGGTAACGAAGCACAAACGCCCCCACCAGGTAGTCCAAGGTGCCCTTTTCC
CCAAGCAGCGCTGMAGGKTCMATCTGGCCTCGCCGAAGTCTCTGCCCAGC
ACGTGGTGCCCCCTCGGGCCAGCGGGGAGGGGGCGAATCCCGGGA CTGCTC
GCCAGGCCTCGGCTCCCCGGAGACTCTTGGGGGTSTGGGCCCCAAGGGTG
ATTCAGGTGCTGCCCTTKCCCCGACCTGGGATGCTTCCCCACGTCTTCT
TTTGTTTTAATGTCCCGGGCCGAGCAGTTGCCGGCGCAATTCATGYTCCG
AGGCCTGAGCCAACCGGAGGCGAGACAAGCACAGGGCCCTGCGCGCAACC

CGGCACCTAAGGAGGCCTGCCCGGTGCAGACTCTCCTGCTCCCACCGGCG
CCCTTCCCTCTAGAGACGCTGAGAGAACGGGAGCTAGTAGCGCCCCCACC
CAACGCCACCTCGGAGACTCCGGCTCCTTCTCTCTCAACTTCGAACAATA
CAAAGTGTGCTAGGAGAAGACAAGATGGCGCCAGCAGGAGGAGCGGAGA
AAGGCAGGGGTGTAAATCTGGCTTCCAAACTGGAAGCGTCAACAAAGGCG
TGGGAGGTCTAACCGCGCAGGCGTGCAGCTTCGGCAAGCTT

SUBSTITUTE SHEET (RULE 26)

Sequence ID No 4

ctagctggtctgagcatctctgcc ATGCGGCTCCCTGTGTGTCTGATCTTGCTAGGACCGC
TTATAG gtaaggagaaatgggaggtgggggagggagggctcatgggcaggagcctgcacctgggtggcc
aaccaatctcttactgaaag CCCAAGGAACAGAGGAAGACTGTCCTCACAAAAAGGCCG
TTACTCTCCTGCCATCCTTCACGATGACACCTACAGCCACAGAAAGCACAGCCA
GCCCTACGACCAGCCACAGGCCACCACCACCAGTCACGGAAATGTCACAGT
TCACACCAGCTCCGGACCCACAACCTGTCACTCATAACCCTGCCACCACCACC
AGTCATGGGAATGCCACAATTTCTCATGCCACAGTTTCTCCCACCACAAATGGC
ACTGCTACTAGTCCAAGATCCTCCACTGTTGGCCCTCACCTGGACCACCTCC
ACCCTCGCCTAGTCCAAGGTCCAAGGGGGCTCTTGGGAACTACACGTGGGGCCA
ACGGCTCCCATCCTTGTGTTTCTCAGCTCCAAGCCCAAATTCAAATCCGAATCCTAT
ACCCAATTCAGGGTGGAAGAAAG gtaaagctaaagtggggcttaaagagggcaagaggcaa
gtcctgggctcggtcagcaggaagaggaagagaagaggaggggataaactggatggagcattctgtgatti
cagaccaccattgcacttctacag GCTTGGGGCATATCTGTTTTGAATCCCAACAAAACC
AAGGTCCAGGGAGGTTGTGACGGTACCCATCCCCACCTGTCTCTCTCATTTC
TTATGGACAGCTTACCTTTGGATTCAAACAG gtatacagcttgagttgtctctatccttattctcc
atatccataacctgtacccccggagcctctgttctgtctgtggacatggatgcctctgtccctgatgccttgagtcctt
gttcacctaag GACCTACATCAGAGCCCGAGTACAGTCTACCTGGACTACATGGCG
GTGGAATACAATGTGTCCTTCCCACAGGCAGCAC gtgagtaatctctctccttaccacacta
aaagtctaggctgggcgtgctgggctggtggggaggactcaggagtcaggactggattgactcttaattactaat
tactgcag AGTGGACATTCATGGCGCAGAATTCATCTCTTCGAGAGCTCCAAGCTC
CCTTGGGCCAAAGCTTCTGCTGTGGAAATGCAAGCATAGTTCTTTCTCCAGCTG
TTACCTTGACCTGCTCTCTCTAAGGCTACAGGCTGCTCAGCTGCCTGACAAGG
GACACTTCGGGCCAT gtaagccctacctacttcttcttcttagagctctcccagtgctctggaaaccttccc

SUBSTITUTE SHEET (RULE 26)

cagaactcttttctagacctccgacctctctacaagactgccttattccccttgctgactgctctcacctatgggtggc
tcctcagcctttctcatcccccttcctctccgtcctccccacctcccaccttagcccgtccaccactgcagcaattct
cagggatcccattattctgccag GTTTCTCTTGCAACCGTGACCAGTCCCTCTTGCTGCC
TCTCATCATTGGCCTGGTCCTCCTCGGCCTCCTCACCTGGTGCTCATCGCC
TTCTGCATCACCCGCAGACGACAATCAACCTACCAGCCCCTCTGA gcattctgcccc
agtccactgtg

SUBSTITUTE SHEET (RULE 26)

CLAIMS

1. A cloned polynucleotide having the function of a
5 transcriptional regulatory sequence (trs) and comprising:
 - (a) a polynucleotide fragment having at least 70% identity to the polynucleotide of Seq ID No. 2;
 - (b) a polynucleotide which is complementary to the polynucleotide of (a); or
 - 10 (c) a polynucleotide comprising at least 15 sequential bases of the polynucleotide of (a) or (b).
2. A polynucleotide according to claim 1 wherein the polynucleotide fragment has at least 80% identity to the polynucleotide of Seq ID No. 2.
- 15 3. A polynucleotide according to claim 1 or 2 wherein the polynucleotide fragment has at least 90% identity to the polynucleotide of Seq ID No. 2.
4. A polynucleotide according to claim 1, 2 or 3 comprising the polynucleotide of Seq ID No. 2.
- 20 5. A polynucleotide comprising the transcriptional regulatory sequence of CD68.
6. An expression cassette comprising a polynucleotide according to any one of the preceding claims and a polynucleotide operatively linked thereto encoding a heterologous polypeptide.
- 25 7. An expression vector comprising the expression cassette as claimed in claim 6.
8. A host cell comprising a vector as claimed in claim 7.
9. A process for producing a polypeptide which process comprises transforming or transfecting a cell with a vector as claimed in
30 claim 7 and culturing the transformed or transfected cell.

- 10 A vector for the integration of an heterologous gene into the genome of a mammalian host cell such that the gene may be expressed in the host cell, the vector comprising a transcriptional regulatory sequence,
5 the said gene and a Locus Control Region capable of eliciting host cell-type restricted, integration site independent, copy number dependent expression of said gene, characterised in that the Locus Control Region is located within a region extending from 14kb upstream to 25 kb downstream of the CD68 gene.
- 10 11 A vector as claimed in claim 10, wherein the Locus Control Region is located within a region extending from 5.5 kb upstream to 12 kb downstream of the CD68 gene.
- 12 A vector as claimed in claim 11, wherein the Locus Control Region is located within a 3 kb BstX1-BstX1 locus immediately upstream of
15 the CD68 gene.
- 13 A mammalian host cell selected from macrophages, monocytes and dendritic cells and their precursors, transformed with a vector as defined according to any one of claims 10 to 12.
- 14 A mammalian host cell as claimed in claim 13 which is a
20 mature macrophage.
- 15 A method of producing a polypeptide, which method comprises culturing a mammalian host cell according to claim 13 or claim 14.
- 16 A method of modifying mammalian stem cells and progenitor
25 cells comprising transforming mammalian stem cells with a vector according to any one of claims 10 to 12.
- 17 Mammalian stem cells and progenitor cells modified as claimed in claim 16, for use in the treatment of a disease condition in a human or animal body.
- 30 18 Use of a vector according to any one of claims 10 to 12 or

mammalian stem cells or progenitor cells according to claim 17, for the manufacture of a medicament for the treatment of a disease condition of the human or animal body caused by a gene deficiency.

19 An isolated polypeptide which is expressed under the control
5 of a CD68 transcriptional regulatory sequence.

20 An isolated polypeptide which is expressed under the control of a transcriptional regulatory sequence comprising a nucleotide sequence as claimed in any one of claims 1 to 5

21 A polynucleotide as claimed in any one of claims 1 to 5, an
10 expression cassette as claimed in claim 6, an expression vector as claimed in claim 7 or a host cell as claimed in claim 8 for use in medical therapy.

22 Use of a polynucleotide as claimed in any one of claims 1 to 5, an expression cassette as claimed in claim 6, an expression vector as claimed in claim 7 or a host cell as claimed in claim 8 in the manufacture of
15 a medicament for use in therapy.

20

1/7

Human CD68 Cosmids




FIG. 1

2/7

1 TGTCTGGAA CCCAGGTGCC TACCTGGTCT GCTGCATATT TGTTTTCTCT
 51 TCCAGCATGG AGATATGGnA CCAAAGGAA CGAGTGCTCA GAGTTTTGAT
 101 TACCAnTGAC CTGCTGGTGA GTAGAGGGAA CTGATAGCAA AGGCAGAAGG
 151 GAGGATCCAA GGTGATTCCC TCTCCAAGGC AAGTTCGGAA AGTAGCAGCT
 201 TGGAAATAGAA TCTGGCATGC CTAAGGCCTT TGGGGAAGTGG GGATGCTTAT
 251 TTCCTCTGCC TTCCTTGGCT GCCCACATGG ATGCCTAAGT GTCTTCCCTC
 301 CGGGATAGAG TGTCTCCGT GCACATGCTG AAGAGTTGTC TTTCTTGACG
 351 TAGGCCAGAG GCATTGATGT GCAGCAGGTT TCTTTAGTCA TCAAcTATGA
 401 CcTTCCCACC AACAGGGAAA ACTATATCCA CAGGTAAGCG TAGATCTGGA
 451 ACATTCCCAAn ACCCTTTCAC ACcTGGCCcT CCCTGGGCTT AAAGCTCCTG
 501 ATATTCTCTCA TCCCCTTCCT TGTTTTCCAG AATCGGTCGA GGTGGACGGT
 551 TTGGCCGTAA AGGTGTGGCT ATTAACATGG TGACAGAAGA AGACAAGAGG
 601 AyTcTTCGAG ACATTGAGAC cTTCTACAAC ACCTCCATTG AGGAAATGCC
 651 CCTCAATGTT GCTGACCTCA TCTGAGGGGC TGTCcTGCCA CCCAsCCCCA
 701 gCCAsGcTC AkyTcTGGG GGCTGAGGAk CwgCAGGAGG GGGGAGGGAA
 751 GGGAGCCAAG GGATGGACAT CTTGTcAtTT TTTTtCTTT GAATAAATGT
 801 CACTTTTTGA GGCAAAAGAA GGAACCGTGA ACATTTTAGA CACCCTTTTC
 851 TTTGGGGTAG GCTCTTGCCC CAGGCGCCGG CTCTTCTCCC AAAAAAAAAA
 901 AAAAAACAcT AaTCCATTTC CCTAACcTAg TAACcTCCAG ATCCCAGAGG
 951 CTCTCCTCAC CTCAGCTGAG CTCCTTTGAA AGTGATTCAA GGGAcTATGT
 1001 CAcTCAGCcT CATTGcTGG ACCAAATcTG GAGGGAGAAC CCCTAAACC
 1051 CcTAAGTGAG GTTGCCAGG GGGTTGTCCC CAGGTGGGGG GAAGCAGGGG
 1101 AGAGAAAATG GTAGCCATTT TtACATTGTT TTGTATAGTA TTTATTGATT
 1151 CAGGAAACAA ACACAAAATT cTGAATAAAA TGACTTGGA ACTGCCTGTT
 1201 TGGGCTTCTC ATTTCTtACC TCCCCTTCCC TCTCCCACCT GmTAcTGGGT
 1251 GCATcTCTGC T.CCCCCCTT .CCCCAGCAG ATGGTTACCT TTGGGCTGTT
 1301 GCTTTCTTGT CACCATCTGA GTTCTCAGAC GCTGGAAAGC CATGTTCTCG
 1351 GCTCTGTGAA tGACAATGcT GAcTGGAGTG CTGCCCCTCT GTAAAGGGcT
 1401 GGGTGTGGAT GGTCACAAGC CCtTcACATG CyTCAGCCAA GAgGAAGTAG
 1451 tACAGGggTC AGCCCAGAgg TCCAGGGGAA AgGAgtgGAA AcCGATTTC
 1501 CCACCAA.GG GAgGGGCcTG TAcTCAGcT GTTCCCATAg cTACTTGCCA

FIG. 2(I)

SUBSTITUTE SHEET (RULE 26)

3/7

1551 CAACTGCCAA GCAAgTTTCG cTGAgTTtGA CACATGG.AT CCC.TGTGGA
1601 TCAAcTGCCc TAgGAcTCcG TTTGCACCCA TgtgACacTG ttGAcTTTGC
1651 CCTGAcgAa. gCAgggcCAa cagtccccta AcTTAATtAC aAaAAcTAAT
1701 GAcTAAGAgA gAgGTGGcTA gAgCTGAgGC CCCTG.AgTC AgGcTGTGGG
1751 TGGGATCaTc tCCAgTACAG GAAgtGAGAc TTTCATTT.C ctCCtTTcCA
1801 Ag.AgAgGGc TGAgGGAgCa gGGTTgAgCa ActGGTGCAg ACAgCCTAgc
1851 TGGAActTTGG GTgAgGc..g gtTCAgCCAT gAgGctGGcT gTgCttTtcT
1901 cGGGGGcCCT GcTGGGGcTA cTGGCAGGTA AGGAGGAAG AgGcTGAGGG
1951 GAGGGGG..c CCCTGGGAGG GAGCcTG.CC CTGGGTTGct AACCATcTCC
2001 T....ct.CT GCCAAAAGCC CAGGGGACAG GGAATGAC.T GTCCTCACAA
2051 AAAATCAGcT ACTTtGcTGC CATCCtTCAC GGTGACACCC ACGGtTACAG
2101 AGAGCACTGG AACAAcCAGC CACAGGACTA CCAAgAGCCA CAAAACCACC

FIG. 2(II)

4/7





FIG. 3

SUBSTITUTE SHEET (RULE 26)

A.



CD68 and Macrosialin Primers

FIG. 4

6/7




FIG. 5

7/7





FIG. 6

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/01209

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/86 C12N15/11 C12N5/10 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	WO 95 33841 A (MEDICAL RES COUNCIL) 14 December 1995 see page 4, line 27 - page 19, line 23 ---	19,20 1-18,21, 22
X A	WO 94 21806 A (MEDICAL RES COUNCIL ;THEREXSYS LTD (GB); DZIERZAK ELAINE ANNE (GB)) 29 September 1994 see page 3, line 34 - page 4, line 10 see page 9, line 28 - page 10, line 13; example III --- -/--	19,20 1-18,21, 22

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the international search

1 September 1997

Date of mailing of the international search report

16.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/01209

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 08635 A (THEREXSYS LIMITED) 30 March 1995	19,20
A	see page 4, line 20 - page 5, line 25 see page 8, line 36 - page 9, line 32 ---	1-18,21, 22
A	BRISTOL-MYERS SQUIBB CANCER SYMP. (1993), 15(APPLICATION OF BASIC SCIENCE TO HEMATOPOIESIS AND TREATMENT OF DISEASE), 21-38 CODEN: BMSSE7, 1993, XP002037064 GROSVELD, FRANK ET AL: "The regulation of the human.beta.-globin locus" see page 23, paragraph 2 - page 26, paragraph 2 see page 29, paragraph 2 - page 33, paragraph 1 -----	1-22

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 97/01209

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Please see Further Information sheet enclosed.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 97/ 01209

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

Remark : Although claim 16, as far as concerning an in vivo method is directed to a method of treatment of the human/animal body that search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/01209

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9533841 A	14-12-95	AU 2678195 A EP 0765396 A	04-01-96 02-04-97
WO 9421806 A	29-09-94	AU 6261494 A CA 2158252 A EP 0689602 A JP 8508642 T	11-10-94 29-09-94 03-01-96 17-09-96
WO 9508635 A	30-03-95	AU 7702694 A EP 0725830 A	10-04-95 14-08-96



4

5

6

7

8

9